Japanese Retailer Aeon Takes Controlling Position In Drug Store Chain CFS
This article was originally published in PharmAsia News
Japan's major retailer Aeon will increase it shares in CFS Corp., a Shizuoka-based drug store chain. The companies agreed that Aeon will increase shares in CFS from 15 percent to 33.3 percent by acquiring a maximum of 28 million CFS shares in a friendly takeover bid. The companies also agreed to set up a team to implement the measures to strengthen branding and improve business. CFS President Kenji Ishida commented that the agreement will increase enterprise value and move the company toward achieving its business goal of total healthcare. Two Aeon executives will be appointed to the CFS board, and Aeon's Managing Director Tetsuo Imoto will become CFS's vice president. (Click here for more-J apanese language
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.